Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in EBV-Positive Lymphoproliferative Disorders and Non-Hodgkin Lymphomas
NCT03258567Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2018
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Epstein-Barr virus-positive lymphoproliferative disorder, Epstein-Barr virus-positive non-Hodgkin lymphoma, sponsored by National Cancer Institute. Started Apr 2018; status: recruiting.
02
Drugs
03
Conditions
Epstein-Barr virus-positive lymphoproliferative disorderEpstein-Barr virus-positive non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03258567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258567.